Great question! Enhertu (fam-trastuzumab deruxtecan) is a targeted therapy used to treat certain types of breast cancer. It's known as an antibody-drug conjugate (ADC) — think of it as a guided missile that seeks out cancer cells and delivers chemotherapy directly into them, helping to limit damage to healthy tissue.
It's Show Full Answer
Great question! Enhertu (fam-trastuzumab deruxtecan) is a targeted therapy used to treat certain types of breast cancer. It's known as an antibody-drug conjugate (ADC) — think of it as a guided missile that seeks out cancer cells and delivers chemotherapy directly into them, helping to limit damage to healthy tissue.
It's approved to treat:
- HER2-positive metastatic breast cancer
- Early-stage breast cancer that returned within six months of completing treatment
- Metastatic breast cancer with low HER2 levels Exciting recent research shows that combining Enhertu with pertuzumab (Perjeta) as a first-line treatment for HER2-positive metastatic breast cancer produced impressive results:
- A 44% lower chance of cancer getting worse or death compared to the current standard treatment
- Cancer did not progress for about 40.7 months (vs. 26.9 months with standard treatment)
- Tumors shrank in about 85% of participants
- Tumors disappeared completely in 15% — nearly double the rate of standard treatment
These results suggest this combination could become a new standard of care for HER2-positive metastatic breast cancer. It's always worth discussing with your oncologist whether Enhertu or the Enhertu + Perjeta combination might be right for your specific situation, as treatment decisions depend on your individual diagnosis and history.
August 16
Great answer. Thank you!!!!
August 22
Join
Your Privacy Choices
